Mitsubishi Tanabe Pharma America - Pipeline, News, & More
Dec 3, 2024 · See the latest status of our innovative investigational therapies and pipeline as well as read stories, explore our company, and connect with us.
News Releases | Mitsubishi Tanabe Pharma Corporation
Aug 27, 2020 · Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. update co-promotion framework for STELARA ®, an anti-IL-12/23p40 monoclonal antibody Distribution will be transferred to Mitsubishi Tanabe Pharma, while the two companies will continue co-promotion of STELARA ® to treat adults with Crohn’s disease in Japan[PDF:385.0 KB]
Mitsubishi Tanabe Pharma America to Discontinue Intravenous …
JERSEY CITY, N.J. October 10, 2024 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the strategic business decision to discontinue intravenous (IV) RADICAVA ® (edaravone), an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS) that was approved by the U.S. Food and Drug Administration (FDA) in May of 2017 ...
Newsroom - Mitsubishi Tanabe Pharma America
Oct 15, 2024 · Discover the latest news and updates from Mitsubishi Tanabe Pharma America. Stay informed on our recent healthcare developments by exploring our news page.
Mitsubishi Tanabe Pharma America Presents Final Results from …
Jun 17, 2024 · Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of final results from the global, multi-center, double-blind, Phase 3b MT-1186-A02 study of oral edaravone in...
Mitsubishi Tanabe Pharma America to Present New ALS …
Dec 4, 2024 · JERSEY CITY, N.J., Dec. 3, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced 10 presentations covering advances in amyotrophic lateral sclerosis (ALS) research at the Motor Neurone Disease Association (MNDA) 35 th International Symposium on ALS/MND, being held in Montreal, Canada, from December 6-8.
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug ...
JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of...
Mitsubishi Tanabe Pharma America, Inc. (MTPA) Stands with the …
May 23, 2024 · Mitsubishi Tanabe Pharma America, Inc. (MTPA) is aware of recent external challenges facing the amyotrophic lateral sclerosis (ALS) treatment landscape.
Mitsubishi Tanabe Pharma America Announces Publication of …
Mar 18, 2024 · Results from the study, which met its primary endpoint and the first four secondary endpoints, showed ND0612 was superior at increasing "ON" time without troublesome dyskinesia and reducing "OFF"...
Dewpoint and Mitsubishi Tanabe partner for ALS treatment
Dec 5, 2024 · The partnership focuses on the development of the TDP-43 small molecule c-mod for amyotrophic lateral sclerosis. Credit: PanuShot/Shutterstock. Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research partnership focusing on the development of the ...
- Some results have been removed